CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PSY-PGx project seeks to personalize psychiatric treatment through pharmacogenetic testing, aiming to improve medication effectiveness and reduce side effects. It plans to conduct a large-scale clinical trial to validate this approach in real-world settings.
Due to the chronic relapsing nature of mental disorders and increased life expectancy, the societal burden of these non-communicable diseases will increase even further.
Treatments for mental disorders are available, but their effect is limited due to patients’ (genetic) heterogeneity, low treatment compliance and frequent side effects.
Only one-third of the patients respond to treatment.
Today, medication selection in psychiatry relies on a trial-and-error approach based mainly on physicians’ e…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Groningen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Planegg
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
FACULTY OF PHARMACY UNIVERSITY OF BELGRADE
Serbia, BELGRADE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
